Profiel
Houssam Zazgad currently works as the Chief Operating Officer & Director at PROMETHERA Biosciences SA. He is currently working as a Director at Hepatic Cell Therapy Support SA since 2020.
Actieve functies van Houssam Zazgad
Bedrijven | Functie | Begin |
---|---|---|
Hepatic Cell Therapy Support SA
Hepatic Cell Therapy Support SA BiotechnologyHealth Technology Part of Catalent, Inc., Hepatic Cell Therapy Support SA is a cell therapy manufacturing facility. The company is based in Charleroi, Belgium. Founded in 2011, the Belgian company operates as a cell therapy manufacturing facility. Hepatic Cell Therapy Support was acquired by Catalent, Inc. from PROMETHERA Biosciences SA on May 06, 2021 for $18.25 million. | Directeur/Bestuurslid | 15-09-2020 |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Operationeel Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Hepatic Cell Therapy Support SA
Hepatic Cell Therapy Support SA BiotechnologyHealth Technology Part of Catalent, Inc., Hepatic Cell Therapy Support SA is a cell therapy manufacturing facility. The company is based in Charleroi, Belgium. Founded in 2011, the Belgian company operates as a cell therapy manufacturing facility. Hepatic Cell Therapy Support was acquired by Catalent, Inc. from PROMETHERA Biosciences SA on May 06, 2021 for $18.25 million. | Health Technology |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |